Biotech Due Diligence Checklist: How to Evaluate a Drug Pipeline and Probability of Approval

Every biotech investor has the same fundamental problem: there are hundreds of biotech stocks, most of them are pre-revenue, and the only way to separate the good ones from the bad ones is to do the work. That work is called due diligence, and if you skip it, you are gambling, not investing.

The problem is that biotech due diligence is different from traditional stock analysis. You cannot just pull up a P/E ratio or look at revenue growth. Instead, you need to understand the drug pipeline, evaluate the clinical data, assess the probability that the FDA will actually approve the drug, figure out whether the company has enough money to get there, and check whether the smart money is betting on the same outcome you are.

In this guide, we walk through a complete due diligence framework for biotech stocks, step by step. By the end, you will have a repeatable checklist you can apply to any biotech company before you invest.

This is Part 3 of the BiopharmaWatch Biotech Investing Masterclass. If you are just getting started, read Part 1: How to Invest in Biotech Stocks first. If you want to understand how to read clinical trial results, check out Part 2: How to Read Clinical Trial Data.

The Biotech Due Diligence Framework

Before diving into the details, here is the full checklist at a glance. Each item below is a step in the process, and we will walk through every one of them in detail.

Step 1: Understand the Drug Pipeline

The pipeline is the single most important thing about a biotech company. It tells you what the company is working on, how far along each program is, and how many chances they have to succeed.

What to look for

• Number of programs. A company with a single drug in development is a binary bet. If that drug fails, the stock goes to near zero. A company with three or four programs has multiple chances to succeed, which reduces your risk. All else being equal, diversified pipelines are safer.
• Stage of development. Drugs in Phase 3 or under FDA review are closer to potential revenue. Drugs in Phase 1 or preclinical are higher risk but can offer more upside if they advance. The ideal portfolio position depends on your risk tolerance.
• Therapeutic area. Some therapeutic areas have higher approval rates than others. Oncology drugs historically have lower approval rates than rare disease drugs. Drugs targeting infectious diseases with unmet need tend to have FDA-friendly regulatory paths.
• Regulatory designations. Look for Breakthrough Therapy, Fast Track, Orphan Drug, and Priority Review designations. These signal that the FDA considers the drug important and is willing to expedite the review. Drugs with breakthrough designation have historically higher approval rates.

Where to find pipeline information

The company's investor relations page usually has a pipeline slide. You can also use the BiopharmaWatch FDA Calendar to see all upcoming catalysts for a specific company by searching its ticker. ClinicalTrials.gov has detailed information on every registered clinical trial, including enrollment status, trial design, and endpoints.

Step 2: Evaluate Clinical Trial Data Quality

Once you know what is in the pipeline, the next step is evaluating how strong the clinical data is. We covered this in depth in Part 2 of this series, but here is the quick checklist:

The most important thing to remember: always read the actual data, not just the press release headline. Companies have an incentive to present their data in the best possible light. Your job is to look past the spin and assess the science objectively.

Step 3: Assess the Probability of Approval (POA)

Probability of Approval is the estimated likelihood that a drug will receive FDA approval. It is based on a combination of historical success rates, clinical data strength, regulatory designations, and the competitive landscape.

How POA scores are calculated

POA is not a single number pulled from one source. It is typically estimated by combining several factors:

• Historical base rates. What percentage of drugs at this stage, in this therapeutic area, have historically received approval? A Phase 3 oncology drug has a different base rate than a Phase 3 rare disease drug.
• Clinical data strength. Drugs with strong, statistically significant efficacy data and clean safety profiles score higher. Drugs with borderline results or safety concerns score lower.
• Regulatory designations. Breakthrough Therapy designation alone increases historical approval rates by roughly 10 to 15 percentage points compared to drugs without it.
• FDA interactions. Positive feedback from a pre-NDA meeting, successful resolution of a Complete Response Letter, or a favorable advisory committee vote all increase POA.
• Competitive landscape. If there are already approved drugs for the same indication, the FDA sets a higher bar. First-in-class drugs for unmet needs have an easier path.

POA benchmarks by stage

You can view POA scores for every upcoming catalyst on the BiopharmaWatch FDA Calendar. Use them as a starting point, not as a guarantee. POA is an estimate, not a prediction.

Step 4: Analyze the Market Opportunity

Even if a drug gets approved, the stock only goes up if there is a large enough commercial opportunity to justify the valuation. Here is what to evaluate:

Patient population

How many people have the disease the drug targets? A drug for a rare disease affecting 10,000 patients can still be enormously profitable if it commands premium pricing (often $100,000 to $500,000 per year for orphan drugs). A drug for a common disease with millions of patients might generate more total revenue but faces more competition and pricing pressure.

Competitive landscape

Is the drug first-in-class, meaning it is the first drug with this mechanism of action? Or is it entering a crowded market with established competitors? First-in-class drugs for unmet needs command the highest valuations. Me-too drugs in crowded markets are much harder to commercialize.

Pricing and reimbursement

Can the company charge enough to justify the development cost? Will insurance companies cover it? In the current environment, payer pushback on drug pricing is real. Look at what comparable drugs are priced at and estimate whether the new drug can achieve similar pricing.

Peak sales estimates

Analysts publish peak sales estimates for drugs in development. These are their best guesses for how much revenue the drug could generate at its peak year. Compare the peak sales estimate to the company's current market cap. If a company with a $500 million market cap has a drug with $2 billion in peak sales potential and a 60% POA, the risk-adjusted value of that drug alone could be worth more than the entire company.

Step 5: Check the Balance Sheet and Cash Runway

This step catches investors off guard more than any other. A company can have great science, strong clinical data, and a clear path to approval, and still see its stock drop because it ran out of money and had to raise capital at a discount.

Key financial metrics for biotech

The cash runway rule of thumb

A company needs to have enough cash to fund operations through its next major catalyst, plus at least 6 months of buffer. If a company has a PDUFA date in 12 months but only 8 months of cash, it will almost certainly need to raise money before the FDA decision. That means dilution, which means downward pressure on the stock price.

Companies with less than 12 months of runway are in the danger zone. Those with 18 to 24 months of runway are in better shape. Companies with more than 24 months of runway funded through their next catalyst are in the strongest position.

Step 6: Read the Hedge Fund and Insider Signals

This is where many biotech investors find their edge. Hedge funds and corporate insiders often have access to better information, deeper analysis, and more experience than individual investors. Watching what they do can give you valuable signals.

Hedge fund positioning

Biotech-focused hedge funds like Baker Brothers, OrbiMed, RA Capital, Perceptive Advisors, and Vivo Capital employ teams of PhDs, MDs, former FDA reviewers, and industry veterans. When these funds build significant positions in a biotech stock, it signals deep conviction in the science and the commercial opportunity.

The BiopharmaWatch Hedge Fund Tracker lets you see exactly which hedge funds hold which biotech stocks, how large their positions are, and whether they have been buying or selling. This is one of the most powerful tools available to individual investors.

What to look for in hedge fund data

• New positions. When a top biotech fund opens a brand-new position, especially ahead of a major catalyst, it is worth investigating why.
• Increasing positions. Funds adding to existing positions signal continued conviction.
• Multiple funds converging. When several independent biotech-focused funds all hold the same stock, it reduces the chance that any one fund is simply wrong.
• Decreasing or exited positions. Funds selling can be a warning sign, especially if the catalyst timeline has not changed.

Insider buying and selling

Insider transactions tell you what the people running the company think about the stock. The key insight is simple: insiders sell for many reasons (taxes, diversification, estate planning), but they only buy for one reason. They think the stock is going up.

• Cluster buying. When multiple insiders buy around the same time, especially ahead of a data readout, it is the strongest insider signal you can get.
• CEO or CMO purchases. These are the people closest to the clinical data. Their purchases carry more weight than a board member who might not understand the science.
• Size relative to compensation. An executive buying $20,000 worth of stock might not mean much if they make $5 million a year. An executive buying $500,000 worth of stock out of pocket is putting real skin in the game.

Step 7: Map Out the Catalyst Timeline

The final step is understanding when the stock could move. Biotech stocks do not drift up gradually like blue-chip dividend payers. They move in sharp bursts around catalysts, and if you do not know when those catalysts are, you are flying blind.

Types of catalysts to track

The BiopharmaWatch FDA Calendar tracks all of these catalysts in one place. You can filter by stage, search by ticker, and see POA scores alongside each event. Make it your first stop when evaluating any biotech stock.

Putting It All Together: A Worked Example

Here is how you might apply this framework to a hypothetical biotech company:

You find a company trading at a $400 million market cap. It has one lead drug in Phase 3 for a rare liver disease with no approved treatments. The Phase 2 data showed a 45% response rate with a p-value of 0.002. The drug has Breakthrough Therapy and Orphan Drug designations. The company has $180 million in cash and burns $15 million per quarter, giving it 12 quarters (3 years) of runway. The Phase 3 readout is expected in 6 months, and if positive, the NDA filing would follow shortly after.

You check the BiopharmaWatch Hedge Fund Tracker and see that Baker Brothers, RA Capital, and OrbiMed all hold positions. The CMO bought $200,000 in shares two weeks ago.

Running through the checklist:

• Pipeline: Single-asset risk, but the drug is in Phase 3 with strong designations.
• Clinical data: Strong Phase 2 data with high statistical significance.
• POA: Phase 3 rare disease with Breakthrough Therapy designation. Estimated 60% to 70%.
• Market opportunity: Rare disease with no approved therapy. Orphan drug pricing ($200K+/year) on a 10,000-patient population = $2 billion potential market.
• Balance sheet: 3 years of cash runway. No near-term dilution risk. Strong financial position.
• Smart money: Three top-tier biotech funds holding. CMO buying with personal money. Strong alignment.
• Catalyst: Phase 3 readout in 6 months. Clear, time-bound catalyst with high potential impact.

This is the kind of setup that professional biotech investors look for. It does not mean the stock is guaranteed to go up. The Phase 3 could fail. But the framework gives you a structured way to evaluate the opportunity and decide whether the risk is worth taking.

Frequently Asked Questions

What is biotech due diligence?

Biotech due diligence is the process of thoroughly researching and evaluating a biotech company before investing. It involves analyzing the drug pipeline, clinical trial data, probability of FDA approval, market opportunity, financial position, hedge fund positioning, and upcoming catalyst timeline. The goal is to make informed investment decisions based on data, not speculation.

What is a Probability of Approval (POA) score?

A Probability of Approval score is an estimate of how likely a drug is to receive FDA approval. It is calculated based on historical success rates for drugs at the same development stage, the strength of clinical data, regulatory designations (like Breakthrough Therapy or Fast Track), and the competitive landscape. You can find POA scores for upcoming catalysts on the BiopharmaWatch FDA Calendar.

How do you evaluate a biotech drug pipeline?

To evaluate a biotech pipeline, look at the number of drug programs (diversified is safer), their development stages (later-stage is lower risk), the diseases they target (unmet medical needs have easier regulatory paths), and any FDA designations they have received. A strong pipeline has multiple programs at different stages across therapeutic areas with genuine unmet need.

What is cash runway in biotech?

Cash runway is how long a biotech company can continue operating at its current spending rate before it runs out of money. You calculate it by dividing the company's cash and equivalents by its quarterly burn rate. A company with $100 million in cash burning $10 million per quarter has 10 quarters (2.5 years) of runway. Companies with less than 12 months of runway are at risk of share dilution through capital raises.

How do I use hedge fund data for biotech investing?

Biotech-focused hedge funds employ teams of scientists and former FDA reviewers to analyze drug pipelines. When multiple top-tier funds hold positions in the same biotech stock, it signals deep conviction in the science. The BiopharmaWatch Hedge Fund Tracker shows which funds hold which biotech stocks, how large their positions are, and whether they have been adding or reducing exposure.

What does insider buying mean in biotech?

Insider buying in biotech occurs when company executives, directors, or officers purchase shares with their own money. Insiders sell for many reasons, but they only buy for one: they believe the stock will go up. Cluster buying by multiple insiders, purchases by the CEO or Chief Medical Officer, and large purchases relative to the insider's compensation are the strongest signals.

What is the difference between NDA and BLA?

An NDA (New Drug Application) is filed for traditional small-molecule drugs like pills and capsules. A BLA (Biologics License Application) is filed for biological products like monoclonal antibodies, gene therapies, and vaccines. Both are submitted to the FDA when a company seeks approval to market a drug. The review process is similar, but biologics typically face more complex manufacturing and regulatory requirements.

What are Breakthrough Therapy and Fast Track designations?

These are special FDA designations for drugs targeting serious conditions. Breakthrough Therapy designation is given when early evidence shows substantial improvement over existing therapies. It provides intensive FDA guidance, rolling review, and organizational commitment. Fast Track designation expedites development and review for drugs filling an unmet medical need. Both designations are associated with higher approval rates and faster review timelines.

What Comes Next

You now have a complete due diligence framework you can apply to any biotech stock. The final piece of the puzzle is understanding how to trade around the catalysts you have identified. In Part 4 of this series, we cover biotech catalyst trading, including how hedge funds position before FDA decisions, what the PDUFA run-up looks like, how to size positions for binary events, and the common mistakes that cost investors money.

In the meantime, put this checklist to work. Pick a biotech stock from the BiopharmaWatch FDA Calendar, run through all seven steps, and see what you find. That is how you build conviction, and conviction is what separates investors from speculators.

This article is for educational purposes only and does not constitute financial or investment advice. Biotech investing carries significant risk. Always do your own research and consider consulting a financial advisor before making investment decisions.